Clinical trials: Chronic Hepatitis B Infections
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
Hepatitis B， Chronic
The Study of Two Different Chinese Traditional Medicine Treatment on Chronic Hepatitis B
Although the incidence of Hepatitis B has been decreased a lot recently years, there are still quite a few chronic hepatitis B patients in China.
- Trial name
- NCT03018821
- Testing
- Standard - Yinchengao Decoction plus Ganlu Detoxification Pill, Entecavir or Tenofovir, Standard - Ge Xia Zhu Yu Decoction
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Xi'an Traditional Medicine Hospital
Chronic Hepatitis B Infection
The Changes of Treg Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03210493
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis B, Chronic, Hepatitis D, Chronic
A Long Term Follow-up Study of Patients From the REP 301 Protocol
The REP 301 treatment protocol involved the treatment of patients with chronic hepatitis B / hepatitis D co-infection with two agents: REP 2139-Ca and pegylated interferon (peg-IFN).
- Trial name
- NCT02876419
- Where
- Moldova
- Volunteers
- 11 people
- Sponsor
- Replicor Inc.
Hepatitis B
Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss
For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate.
- Trial name
- NCT01599130
- Testing
- Entecavir, Peginterferon alfa-2a
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Chronic Hepatitis B
Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF
In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs), majority of these CHB patients experienced drug resistance and switched to Tenofovir disoproxil fumaratate(TDF).
- Trial name
- SWITAF (NCT03356834)
- Testing
- Tenofovir alafenamide(TAF), Tenofovir disoproxil fumarate(TDF)
- Where
- Hong Kong
- Volunteers
- 575 people
- Sponsor
- Humanity and Health Research Centre
Hepatitis B， Chronic
Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers
To evaluate the safety and tolerability of Hepalatide(L47) and characterize the clinical pharmacokinetics in healthy volunteers.
- Trial name
- NCT03023787
- Testing
- Hepalatide
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers
- Conditions
- Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas, Chronic Hepatitis B, Lymphoma, Small Lymphocytic
- Trial name
- NCT02991638
- Testing
- Ibrutinib
- Where
- Hong Kong
- Volunteers
- 62 people
- Sponsor
- The University of Hong Kong
Chronic Hepatitis B
The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules
The Safety, Antiviral Activity, and pharmacokinetics of Morphothiadine Mesilate Capsules/Ritonavir Tablets in Patients with Chronic Hepatitis B
- Trial name
- NCT03638076
- Testing
- GLS4, RTV
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis B, Chronic
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
This is a multi centre, two parallel arm, randomized, open-label, Phase 2a experimental study of oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral effect when administered to non-treated…
- Trial name
- NCT04365933
- Testing
- EYP001a, Entecavir, Pegylated interferon alpha2a
- Where
- 6 sites in Hong Kong, South Korea and 1 more
- Volunteers
- 20 people
- Sponsor
- Enyo Pharma
Hepatitis B, Chronic
A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy of the study intervention based on hepatitis B surface antigen (HBsAg) levels.
- Trial name
- OSPREY (NCT05123599)
- Testing
- JNJ-73763989, JNJ-64300535, ETV monohydrate
- Where
- 13 sites in Belgium, France and 6 more
- Volunteers
- 24 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis B, Liver Cirrhosis
Entecavir for Decompensated HBV Cirrhosis
Entecavir (ETV) and tenofovir (TDF) are the first-line drugs for treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV infection gradually progress to liver cirrhosis.
- Trial name
- NCT03345498
- Testing
- Entecavir
- Where
- India
- Volunteers
- 32 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Hepatitis B, Chronic
Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B
In order to clarify the association between HBV mutations appearing before and during interferon therapy and the therapeutic effects, serial serum samples from 100 HBeAg-positive CHB patients undergoing peginterferon alfa-2a…
- Trial name
- NCT01311947
- Testing
- Peginterferon alfa-2a
- Where
- Taiwan
- Volunteers
- 103 people
- Sponsor
- China Medical University Hospital
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
This single arm study will assess the efficacy and safety of PEGASYS in patients with chronic hepatitis B who are either treatment-naive, or who have failed lamivudine- or interferon-treatment in the past.
- Trial name
- NCT00487747
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 23 sites in Russia
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
HIV-1-infection, Hepatitis C, Chronic
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
The study hypothesis is to determine the feasibility of switching HIV-HCV co-infected patients receiving methadone or buprenorphine/naloxone as opioid substitution therapy with suppressed HIV RNA viral load on current…
- Conditions
- HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence, Opioid Dependence
- Trial name
- NCT03549312
- Testing
- Genvoya, Epclusa, Biktarvy
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area
Chronic Hepatitis B
An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine
An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine.
- Trial name
- NCT01264107
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Bukwang Pharmaceutical
HEPATITIS B CHRONIC
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
- Trial name
- ELIMINATE-B (NCT06680232)
- Testing
- PBGENE-HBV
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 45 people
- Sponsor
- Precision BioSciences, Inc.
Chronic Hepatitis b, Non-Alcoholic Fatty Liver Disease
Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis
Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled.
- Trial name
- NCT05786963
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Hepatitis B, Chronic
A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy participants after single and multiple doses, and evaluate the preliminary efficacy of AHB-137…
- Trial name
- NCT06115993
- Testing
- AHB-137 injection
- Where
- 3 sites in China
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
Chronic Hepatitis B
Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)
According to published literature, treatment with pegylated interferon (Peg-IFN) is associated with end of treatment response in treatment naive patients with chronic hepatitis B (CHB).
- Trial name
- Bangabandhu (NCT01589952)
- Testing
- Pegalyted interferon, Entecavir
- Where
- Bangladesh
- Volunteers
- 20 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.